Murideoxycholic Acid (Synonyms: MDCA, Murocholic Acid, NSC 18166) |
| Catalog No.GC40966 |
El Ácido murideoxicÓlico es un Ácido biliar 6 beta-hidroxilado.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 668-49-5
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Murideoxycholic acid (MDCA) is a secondary bile acid produced from α-muricholic acid and β-muricholic acid.[1] It is also a metabolite of lithocholic acid in liver S9 fractions from humans and other species.[2] MDCA prevents gallstone formation in hamsters fed a lithogenic diet but does not resolve gallstones in prairie dogs fed a high cholesterol diet.[3],[4] Gallstones formed during MDCA administration after a high cholesterol diet are comprised of an insoluble calcium salt of murideoxycholyl taurine.[4] In humans, MDCA is rapidly absorbed and is metabolized as an endogenous bile acid with a half-life of approximately 3.5 days.[5]
Reference:
[1]. Wahlström, A., Sayin, S.I., Marschall, H.-I., et al. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 24(1), 41-50 (2016).
[2]. Thakare, R., Alamoudi, J.A., Gautam, N., et al. Species differences in bile acids II. Bile acid metabolism. J. Appl. Toxicol. 38(10), 1336-1352 (2018).
[3]. Cohen, B.I., Matoba, N., Mosbach, E.H., et al. Bile acids substituted in the 6 position prevent cholesterol gallstone formation in the hamster. Gastroenterology 98(2), 397-405 (1990).
[4]. Cohen, B.I., Ayyad, N., Mosbach, E.H., et al. Replacement of cholesterol gallstones by murideoxycholyl taurine gallstones in prairie dogs fed murideoxycholic acid. Hepatology 14(1), 158-168 (1991).
[5]. Khallou, J., Legrand-Defretin, V., Parquet, M., et al. Metabolism and time-course excretion of murideoxycholic acid, a 6 β-hydroxylated bile acid, in humans. J. Hepatol. 17(3), 364-372 (1993).
| Cas No. | 668-49-5 | SDF | |
| Sinónimos | MDCA, Murocholic Acid, NSC 18166 | ||
| Chemical Name | 5β-3α,6β-dihydroxy-cholan-24-oic acid | ||
| Canonical SMILES | C[C@H](CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])C[C@@H](O)[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@@]21C | ||
| Formula | C24H40O4 | M.Wt | 392.6 |
| Solubility | 20mg/mL in ethanol or DMSO, 30mg/mL in DMF | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5471 mL | 12.7356 mL | 25.4712 mL |
| 5 mM | 509.4 μL | 2.5471 mL | 5.0942 mL |
| 10 mM | 254.7 μL | 1.2736 mL | 2.5471 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 12 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *